Altered glucose metabolism has been targeted as a therapeutic strategy in HD; the hypoglycemic agent exendin-4, a GLP-1R agonist, increased insulin secretion/sensitivity, motor coordination and lifespan in a HD mouse model54. Here, GLP1R is linked to Huntington disease.